NCT06516445View on ClinicalTrials.gov

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

June 28, 2025

Study Completion Date

June 28, 2026

Conditions
Colorectal Cancer
Interventions
RADIATION

SCRT

5×5Gy，5Gy/d，QD，D1-D5

DRUG

Camrelizumab

200mg, D1, ivgtt, Q3W, C1-4

DRUG

Fluzoparib

100mg, BID, PO, Q3W, C1-4

DRUG

CAPEOX

Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4

Trial Locations (1)

430079

RECRUITING

Tongji hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER